Advertisement

Rheumatology International

, Volume 31, Issue 2, pp 263–267 | Cite as

Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study

  • Theodoros DimitroulasEmail author
  • Georgios Giannakoulas
  • Hariklia Dimitroula
  • Tilemahos Sfetsios
  • Despina Parcharidou
  • Haralambos Karvounis
  • Loukas Settas
Short Communication

Abstract

Systemic sclerosis is a connective tissue disease, which may lead to elevated pulmonary arterial pressure due to pulmonary arterial hypertension and/or left ventricular diastolic dysfunction. Uric acid (UA) has been shown to be elevated in patients with pulmonary hypertension (PH) and heart failure. We aimed to investigate the potent relationship between serum UA and pulmonary pressure as well as functional capacity in patients with SSc. We studied 66 patients (mean age 57.7 ± 12.1 years, 63 women), presenting with SSc. Systolic pulmonary artery pressure assessed by echocardiography, lung function tests, six-minute walk test (6MWT) and serum UA levels were recorded in all patients. In 24 (36%) patients, the diagnosis of PH was established by echocardiography (systolic pulmonary artery pressure ≥40 mmHg). Patients with PH had higher UA serum levels compared to patients without PH (5.1 ± 2.1 mg/dl vs. 4.2 ± 0.9 mg/dl, p = 0.04). Among patients with PH, UA values were inversely correlated with the SMWT distance (r = −0.51, p = 0.01). Serum UA values increased in proportion to the functional capacity in PH patients with scleroderma. Further investigations in prospective studies will unfold in detail the pathophysiological significance of UA in SSc patients with PH and determine its role as a prognostic marker in the assessment and monitoring of the disease.

Keywords

Uric acid Systemic sclerosis Pulmonary hypertension Six-minute walking test 

Notes

Acknowledgments

Dr. Giannakoulas has received funding from the Hellenic Atherosclerosis Society.

Conflict of interest

The authors have to declare no conflicts of interest.

References

  1. 1.
    Teh CL, Kuan YC, Wong JS (2009) Systemic sclerosis in Sarawak: a profile of patients treated in the Sarawak General Hospital. Rheumatol Int 29:1243–1245CrossRefPubMedGoogle Scholar
  2. 2.
    Toya SP, Tzelepis GE (2009) The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications. Rheumatol Int 29:861–868CrossRefPubMedGoogle Scholar
  3. 3.
    Rosato E, Maione S, Vitarelli A et al (2009) Regional diastolic function by tissue Doppler echocardiography in systemic sclerosis: correlation with clinical variables. Rheumatol Int 29:913–919CrossRefPubMedGoogle Scholar
  4. 4.
    Hachulla E, Gressin V, Guillevin L et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52:3792–3800CrossRefPubMedGoogle Scholar
  5. 5.
    Mukerjee D, St George D, Coleiro B et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62:1088–1093CrossRefPubMedGoogle Scholar
  6. 6.
    Hachulla E, de Groote P, Gressin V et al (2009) Itinér AIR-Sclérodermie Study Group. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 60:1831–1839CrossRefPubMedGoogle Scholar
  7. 7.
    Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944CrossRefPubMedGoogle Scholar
  8. 8.
    Leyva F, Anker S, Swan JW et al (1997) Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 18:858–865PubMedGoogle Scholar
  9. 9.
    Braghiroli A, Sacco C, Erbetta M, Ruga V, Donner CF (1993) Overnight urinary uric acid: creatinine ratio for detection of sleep hypoxemia. Validation study in chronic obstructive pulmonary disease and obstructive sleep apnea before and after treatment with nasal continuous positive airway pressure. Am Rev Respir Dis 148:173–178PubMedGoogle Scholar
  10. 10.
    Sari I, Akar S, Pakoz B (2009) Hyperuricemia and its related factors in an urban population, Izmir, Turkey. Rheumatol Int 29:869–874CrossRefPubMedGoogle Scholar
  11. 11.
    Yang Z, Liang Y, Xi W et al. (2010) Association of serum uric acid with lupus nephritis in systemic lupus erythematosus. Rheumatol Int (in press)Google Scholar
  12. 12.
    De Leonardis F, Govoni M, Colina M et al (2007) Elderly-onset gout: a review. Rheumatol Int 28:1–6CrossRefPubMedGoogle Scholar
  13. 13.
    Nagaya N, Uematsu M, Satoh T et al (1999) Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 160:487–492PubMedGoogle Scholar
  14. 14.
    Bendayan D, Shitrit D, Ygla M, Huerta M, Fink G, Kramer MR (2003) Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. Respir Med 97:130–133CrossRefPubMedGoogle Scholar
  15. 15.
    Voelkel MA, Wynne KM, Badesch DB, Groves BM, Voelkel NF (2000) Hyperuricemia in severe pulmonary hypertension. Chest 117:19–24CrossRefPubMedGoogle Scholar
  16. 16.
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of the systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRefGoogle Scholar
  17. 17.
    Quadrelli SA, Molinari L, Ciallella LM et al (2009) Patterns of pulmonary function in smoking and nonsmoking patients with progressive systemic sclerosis. Rheumatol Int 29:995–999CrossRefPubMedGoogle Scholar
  18. 18.
    Currie P, Seward J, Reeder G (1985) Continuous-wave Doppler echocardiographic assessment of severity of calcific aortic stenosis: a simultaneous Doppler-catheter correlative study in 100 adult patients. Circulation 71:1162–1169PubMedGoogle Scholar
  19. 19.
    Nagueh S, Kopelen H, Zoghbi W (1996) Relation of mean right atrial pressure to echocardiographic and Doppler parameters of right atrial and right ventricular function. Circulation 93:1160–1169PubMedGoogle Scholar
  20. 20.
    Mukerjee D, St George D, Knight C et al (2004) Echocardiography and pulmonary function as screening tests for pulmonary arterialhypertension in systemic sclerosis. Rheumatology 43:461–466CrossRefPubMedGoogle Scholar
  21. 21.
    ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117Google Scholar
  22. 22.
    Leyva F, Anker SD, Godsland IF et al (1998) Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 19:1814–1822CrossRefPubMedGoogle Scholar
  23. 23.
    Alcaino H, Greig D, Chiong M et al (2008) Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail 10:646–651CrossRefPubMedGoogle Scholar
  24. 24.
    Frent-Cornateanu R, Mihai C, Stoian I, Lixandru D, Bara C, Moldoveanu E (2008) Antioxidant defense capacity in scleroderma patients. Clin Chem Lab Med 46:836–841CrossRefGoogle Scholar
  25. 25.
    Bergamini C, Cicoira M, Rossi A, Vassanelli C (2009) Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 11:444–452CrossRefPubMedGoogle Scholar
  26. 26.
    Dimitroulas T, Giannakoulas G, Karvounis H, Gatzoulis MA, Settas L (2010) Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension. Semin Arthritis Rheum 39:278–284CrossRefPubMedGoogle Scholar
  27. 27.
    Mukerjee D, Yap LB, Holmes AM et al (2003) Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 97:1230–1236CrossRefPubMedGoogle Scholar
  28. 28.
    Allanore Y, Borderie D, Meune C et al (2003) N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 48:3503–3508CrossRefPubMedGoogle Scholar
  29. 29.
    Dimitroulas T, Giannakoulas G, Karvounis H et al (2007) Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. Int J Cardiol 121:135–137CrossRefPubMedGoogle Scholar
  30. 30.
    Dimitroulas T, Giannakoulas G, Sfetsios T et al (2008) Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology 47:1682–1685CrossRefPubMedGoogle Scholar
  31. 31.
    Papaioannou AI, Zakynthinos E, Kostikas K et al (2009) Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulm Med 9:18CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Theodoros Dimitroulas
    • 1
    Email author
  • Georgios Giannakoulas
    • 2
  • Hariklia Dimitroula
    • 2
  • Tilemahos Sfetsios
    • 1
  • Despina Parcharidou
    • 2
  • Haralambos Karvounis
    • 2
  • Loukas Settas
    • 1
  1. 1.First Department of Internal MedicineAHEPA University HospitalThessalonikiGreece
  2. 2.Cardiology DepartmentAHEPA University HospitalThessalonikiGreece

Personalised recommendations